Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Sanofi unveils $20bn US investment to boost R&D and manufacturing presence

The company is the latest major drugmaker to announce a significant investment in the country

- PMLiVE

MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

- PMLiVE

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

The companies will launch four development programmes for potential small molecule therapies

- PMLiVE

Eli Lilly to expand long-standing Purdue University partnership with $250m investment

The alliance will aim to bring medicines to patients faster using advanced technologies

- PMLiVE

AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer

An estimated 226,650 people will be diagnosed with lung cancer in the US this year

- PMLiVE

Why Health Comms Teams Can’t Afford to Skip the Mid-Year Review

New McKinsey and Gartner data show that organisations who regularly reset strategy can outperform peers by up to 60%. In fast-moving health communications, the mid-year review is a crucial but...

Fox&Cat

- PMLiVE

GSK to acquire Boston’s liver disease candidate efimosfermin in deal worth up to $2bn

Steatotic liver disease affects approximately 5% of the global population

- PMLiVE

Cytokinetics shares positive phase 3 results for aficamten in heart disease

Up to one in 500 people in the UK and US are living with hypertrophic cardiomyopathy

- PMLiVE

Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis

The drug has already been approved in the US to treat patients with non-cirrhotic MASH

- PMLiVE

Roche’s Perjeta-based breast cancer regimen shows sustained survival benefits

Approximately 56,800 new breast cancer cases are diagnosed in the UK every year

- PMLiVE

Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

- PMLiVE

Eli Lilly’s Zepbound shows superiority in head-to-head weight loss study

Patients treated with Lilly’s drug achieved an average weight reduction of 20.2%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links